Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients

Muhammad A Rana, Mubashar Hashmi, Ahad Qayyum, Rizwan Pervaiz, Muhammad Saleem, Muhammad Faisal Munir, Muhammad Muneeb Ullah Saif, Muhammad A Rana, Mubashar Hashmi, Ahad Qayyum, Rizwan Pervaiz, Muhammad Saleem, Muhammad Faisal Munir, Muhammad Muneeb Ullah Saif

Abstract

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the reason for the global pandemic that started from Wuhan, China, in December 2019, known as coronavirus diseases 2019 (COVID-19). Acute respiratory distress syndrome happened in COVID-19 not just because of uncontrolled viral replication but also because of an uncontrolled immune reaction from the host. That's why antiviral and anti-inflammatory treatments have become an increasing concern for clinicians. Methods A retrospective quasi-experimental study design was used to assess the effectiveness of methylprednisolone and dexamethasone in the improvement of PaO2/FiO2 (P/F) ratio in COVID-19 patients. We included 60 participants for this study by using a convenient sampling technique and divided them into two groups with 30 patients in each group. Group 1 was given dexamethasone 8 mg twice daily, and group 1 given methylprednisolone 40 mg twice daily for eight days. We recorded C-reactive protein (CRP), serum ferritin level, and P/F ratio before administration of both drugs and after administration of drugs for eight days. We used the paired t-test to assess the effect of both drugs on the P/F ratio of participants. Results The initial mean CRP in group 1 was 110.34, which reduced to 19.45 after administration of dexamethasone; similarly, the CRP in group 2 was 108.65, which reduced to 43.82 after administering methylprednisolone for eight days. In P/F ratio improvement, the calculated significance value for dexamethasone (p=0.000) was less than the table value at 0.05 in all sections, p-value for methylprednisolone (p=0.009) was also less than the table value at 0.05, which shows that both dexamethasone and methylprednisolone were effective in improving P/F ratio. Calculated p-value for dexamethasone (p=0.000) was lower than the calculated p-value for methylprednisolone (p=0.009), which shows that dexamethasone is more effective as compare to methylprednisolone. Conclusions Steroid therapy is effective in controlling inflammation markers, and especially dexamethasone is significantly effective in improving the P/F ratio in COVID-19 patients.

Keywords: covid induced ards; covid-19; cytokines release syndrome; dexamethasone; inflammatory markers; methylprednisolone; oxygenation; p/f ratio; ratio of partial pressure of arterial oxygen and fraction of inspired oxygen; sars-cov-2.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2020, Rana et al.

Figures

Figure 1. Sex distribution for group 1…
Figure 1. Sex distribution for group 1 (A) and group 2 (B)

References

    1. The effect of human mobility and control measures on the COVID-19 epidemic in China. Kraemer MU, Yang CH, Gutierrez B, et al. Science. 2020;368:493–497.
    1. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Xu Z, Shi L, Wang Y, et al. Lancet Respir Med. 2020;8:420–422.
    1. COVID-19 infection: the perspectives on immune responses. Shi Y, Wang Y, Shao C, et al. Cell Death Differ. 2020;27:1451–1454.
    1. Implications of COVID-19 in pediatric rheumatology. Batu ED, Özen S. Rheumatol Int. 2020;40:1193–1213.
    1. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers. Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. World J Crit Care Med. 2019;8:59–71.
    1. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Villar J, Ferrando C, Martínez D, et al. Lancet Respir Med. 2020;8:267–276.
    1. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Zhou W, Liu Y, Tian D, et al. Signal Transduct Target Ther. 2020;5:18.
    1. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Wang Y, Jiang W, He Q, et al. Signal Transduct Target Ther. 2020;5:57.
    1. On the use of corticosteroids for 2019-nCoV pneumonia. Shang L, Zhao J, Hu Y, Du R, Cao B. Lancet. 2020;395:683–684.
    1. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. Wu C, Chen X, Cai Y, et al. JAMA Intern Med. 2020;180:1–11.
    1. Viral clearance after early corticosteroid treatment in patients with moderate or severe COVID-19 [PREPRINT] Spagnuolo V, Guffanti M, Galli L, et al. Research Square. 2020
    1. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Man SF, Sin DD. Proc Am Thorac Soc. 2005;2:78–82.
    1. Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia. Kawamata R, Yokoyama K, Sato M, et al. J Infect Chemother. 2015;21:783–789.

Source: PubMed

3
Iratkozz fel